Improving the Prognosis for Patients with BRAF-mutant and/or MSI-H mCRC
Interactive case-based CME activity
Click the "View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
• Describe appropriate biomarker testing recommended for mCRC and explain the importance of biomarker testing for therapy selection
• Interpret the latest clinical trial evidence for BRAF-mutant, MSI-H CRC
• Introduce recommended treatment approaches for BRAF-mutant, MSI-H CRC
Associate Professor of Oncology
Sidney Kimmel Cancer Center
Johns Hopkins University School of Medicine
The following financial relationships have been provided:
Dung Le, MD
Advisory Board/Panel Member: Bristol Myers Squibb
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.